SAGE Therapeutics, Inc. is a biopharmaceutical company, which engages in providing solutions to brain health medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 353 full-time employees. The company went IPO on 2014-07-18. The firm has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. The company is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.

Industry: Pharmaceutical Preparations Peers: ACADIA Pharmaceuticals Inc BioCryst Pharmaceuticals Inc EQRx, Inc. Fate Therapeutics Inc Insmed Inc Prometheus Biosciences, Inc. Relay Therapeutics Inc Prokidney Corp Vir Biotechnology Inc